model,flat_path,key_cat,val_cat,ref_val,pred_val,val_match,sim,score_status,piece,norm_path,from_pred,in_ref,in_pred,type_mismatch,is_enum,sim_failed
Claude-4.5-Sonnet,protocolSection.identificationModule.nctId,TP,TP,NCT03170388,NCT03170388,True,1.0,exact,NCTId,protocolSection.identificationModule.nctId,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.briefTitle,TP,TP,"A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris","A phase II, double-blind, multicenter, randomized, 12-week study of triple-combination, fixed-dose topical clindamycin phosphate 1.2%/benzoyl peroxide (BPO) 3.1%/adapalene 0.15% (IDP-126) gel for the treatment of acne",True,0.84,success,BriefTitle,protocolSection.identificationModule.briefTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.identificationModule.officialTitle,TP,TP,"A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris","Evaluation of the efficacy and safety of triple-combination, fixed-dose topical clindamycin phosphate 1.2%/benzoyl peroxide (BPO) 3.1%/adapalene 0.15% (IDP-126) gel for the treatment of acne",True,0.86,success,OfficialTitle,protocolSection.identificationModule.officialTitle,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.briefSummary,TP,TP,"A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study in the Treatment of Acne Vulgaris","This phase II, double-blind, multicenter, randomized, 12-week study evaluated the efficacy and safety of a novel triple-combination fixed-dose topical gel containing clindamycin phosphate 1.2%, benzoyl peroxide 3.1%, and adapalene 0.15% (IDP-126) for the treatment of moderate-to-severe acne. The study compared IDP-126 to vehicle gel and three component dyad gels (BPO/adapalene, clindamycin/BPO, and clindamycin/adapalene) in participants aged 9 years and older. The hypothesis was that combining an antibiotic, antibacterial, and retinoid in a single formulation would provide greater efficacy and tolerability than single or dyad treatments while potentially improving patient compliance and reducing antibiotic resistance.",True,0.86,success,BriefSummary,protocolSection.descriptionModule.briefSummary,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.descriptionModule.detailedDescription,TP,TP,"A Phase 2, Multicenter, Randomized, Double-Blind, Vehicle Controlled, Parallel-Group, Clinical Study Comparing the Efficacy and Safety of IDP-126 Gel in the Treatment of Acne Vulgaris","In this phase II, multicenter, randomized, double-blind, parallel-group, vehicle-controlled study, 741 participants aged ≥9 years with moderate (EGSS 3) or severe (EGSS 4) acne were enrolled from 31 study centers in the USA and four in Canada. Eligible participants had 30-100 inflammatory lesions (pustules, papules, and nodules), 35-150 noninflammatory lesions (closed and open comedones), and two or fewer nodules. Participants were equally randomized to receive one of five treatments applied to the face once daily for 12 weeks: clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15% gel (IDP-126); one of three component dyads (BPO/adapalene, clindamycin/BPO, or clindamycin/adapalene); or vehicle gel. All active dyads were formulated with the same active drug concentrations and within the same vehicle as IDP-126.

Coprimary endpoints were treatment success at week 12 (≥2-grade reduction from baseline in EGSS and clear/almost clear skin) and least-squares mean absolute changes from baseline in inflammatory and noninflammatory lesion counts to week 12. Secondary and post hoc analyses included treatment success and ≥2-grade EGSS reduction by study visit, percent changes in lesion counts, and quality-of-life assessments using the Acne-Specific Quality of Life (Acne-QoL) questionnaire. Safety assessments included treatment-emergent adverse events, investigator-assessed cutaneous safety (scaling, erythema, hypopigmentation, hyperpigmentation), and participant-reported tolerability (itching, burning, stinging).

IDP-126 is formulated as an aqueous gel with no alcohol, preservatives, occlusive agents, or surfactants. It is pH balanced for the skin and contains propylene glycol as a hydrating humectant. BPO and adapalene are micronized for better penetration of the pilosebaceous unit, and all ingredients are contained within a polymeric gel for even distribution on the skin. The combination targets three of the four acne pathogenic pathways: adapalene normalizes keratinocyte proliferation and has anti-inflammatory properties; BPO provides antibacterial activity with mild comedolytic effects; and clindamycin reduces C. acnes colonization with anti-inflammatory effects. The study aimed to demonstrate that this triple combination would provide superior efficacy to the component dyads while maintaining good tolerability.",True,0.93,success,DetailedDescription,protocolSection.descriptionModule.detailedDescription,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.conditions,TP,TP,['Acne Vulgaris'],"['Acne Vulgaris', 'Moderate Acne', 'Severe Acne']",True,1.0,superset,Condition,protocolSection.conditionsModule.conditions,False,True,True,False,False,False
Claude-4.5-Sonnet,protocolSection.conditionsModule.keywords,EV,EV,,"['Acne', 'Acne Vulgaris', 'Moderate-to-severe acne', 'Clindamycin', 'Benzoyl peroxide', 'Adapalene', 'Triple-combination therapy', 'Fixed-dose combination', 'Topical treatment', 'Retinoid', 'Antibiotic', 'Antibacterial', 'IDP-126']",,,,Keyword,protocolSection.conditionsModule.keywords,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.studyType,FN,FN,INTERVENTIONAL,,False,0.0,,StudyType,protocolSection.designModule.studyType,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.phases,FN,FN,['PHASE2'],,False,0.0,,Phase,protocolSection.designModule.phases,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.allocation,FN,FN,RANDOMIZED,,False,0.0,,DesignAllocation,protocolSection.designModule.designInfo.allocation,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.interventionModel,FN,FN,PARALLEL,,False,0.0,,DesignInterventionModel,protocolSection.designModule.designInfo.interventionModel,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.masking,FN,FN,TRIPLE,,False,0.0,,DesignMasking,protocolSection.designModule.designInfo.maskingInfo.masking,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.designInfo.maskingInfo.whoMasked,FN,FN,"['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR']",,False,0.0,,DesignWhoMasked,protocolSection.designModule.designInfo.maskingInfo.whoMasked,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.enrollmentInfo.count,FN,FN,741,,False,0.0,,EnrollmentCount,protocolSection.designModule.enrollmentInfo.count,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.eligibilityCriteria,FN,FN,"Inclusion Criteria:

1. Male or female at least 9 years of age and older.
2. Written and verbal informed consent must be obtained. Subjects less than age of consent must sign an assent for the study and a parent or a legal guardian must sign the informed consent (if subject reaches age of consent during the study they should be re-consented at the next study visit).
3. Subject must have an EGSS of 3 (moderate) or 4 (severe) at the baseline visit.
4. Subjects with a facial acne inflammatory lesion (papules, pustules, and nodules) count no less than 20, but no more than 100.
5. Subjects with a facial acne non-inflammatory lesion (open and closed comedones) count no less than 30, but no more than 150.
6. Subjects with 2 or fewer facial nodules

Exclusion Criteria:

1. Use of an investigational drug or device within 30 days of enrollment or participation in a research study concurrent with this study.
2. Any dermatological conditions on the face that could interfere with clinical evaluations such as acne conglobata, acne fulminans, secondary acne, perioral dermatitis, clinically significant rosacea, gram negative folliculitis, dermatitis, eczema.
3. Any underlying disease(s) or some other dermatological condition of the face that requires the use of interfering topical or systemic therapy or makes evaluations and lesion count inconclusive.
4. Subjects with a facial beard or mustache that could interfere with the study assessments.
5. Subjects with more than 2 facial nodules.
6. Evidence or history of cosmetic-related acne.",,False,0.0,,EligibilityCriteria,protocolSection.eligibilityModule.eligibilityCriteria,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.healthyVolunteers,FN,FN,False,,False,0.0,,HealthyVolunteers,protocolSection.eligibilityModule.healthyVolunteers,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.sex,FN,FN,ALL,,False,0.0,,Sex,protocolSection.eligibilityModule.sex,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.minimumAge,FN,FN,9 Years,,False,0.0,,MinimumAge,protocolSection.eligibilityModule.minimumAge,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.maximumAge,FN,FN,99 Years,,False,0.0,,MaximumAge,protocolSection.eligibilityModule.maximumAge,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.stdAges,FN,FN,"['CHILD', 'ADULT', 'OLDER_ADULT']",,False,0.0,,StdAge,protocolSection.eligibilityModule.stdAges,False,True,False,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameters.designModule.designInfo.allocation,FP,FP,,RANDOMIZED,False,0.0,,,protocolSection.designModule.parameters.designModule.designInfo.allocation,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameters.designModule.designInfo.interventionModel,FP,FP,,PARALLEL,False,0.0,,,protocolSection.designModule.parameters.designModule.designInfo.interventionModel,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameters.designModule.designInfo.interventionModelDescription,FP,FP,,Participants were equally randomized to receive one of five treatments: clindamycin phosphate 1.2%/BPO 3.1%/adapalene 0.15% gel (IDP-126); one of the three component dyads formulated with the same active drug concentration and within the same vehicle as IDP-126 (BPO 3.1%/adapalene 0.15% gel; clindamycin phosphate 1.2%/BPO 3.1% gel; clindamycin phosphate 1.2%/adapalene 0.15% gel); or vehicle gel.,False,0.0,,,protocolSection.designModule.parameters.designModule.designInfo.interventionModelDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameters.designModule.designInfo.maskingInfo.masking,FP,FP,,DOUBLE,False,0.0,,,protocolSection.designModule.parameters.designModule.designInfo.maskingInfo.masking,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameters.designModule.designInfo.maskingInfo.maskingDescription,FP,FP,,"This was a double-blind study. Identically labeled/packaged study drug kits were dispensed to participants at baseline and weeks 4 and 8 by study center staff, based on a randomization code assigned by the central randomization system.",False,0.0,,,protocolSection.designModule.parameters.designModule.designInfo.maskingInfo.maskingDescription,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameters.designModule.designInfo.maskingInfo.whoMasked,FP,FP,,"['PARTICIPANT', 'INVESTIGATOR']",False,0.0,,,protocolSection.designModule.parameters.designModule.designInfo.maskingInfo.whoMasked,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameters.designModule.designInfo.primaryPurpose,FP,FP,,TREATMENT,False,0.0,,,protocolSection.designModule.parameters.designModule.designInfo.primaryPurpose,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameters.designModule.enrollmentInfo.count,FP,FP,,741,False,0.0,,,protocolSection.designModule.parameters.designModule.enrollmentInfo.count,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameters.designModule.enrollmentInfo.type,FP,FP,,ACTUAL,False,0.0,,,protocolSection.designModule.parameters.designModule.enrollmentInfo.type,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameters.designModule.patientRegistry,FP,FP,,False,False,0.0,,,protocolSection.designModule.parameters.designModule.patientRegistry,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameters.designModule.phases,FP,FP,,['PHASE2'],False,0.0,,,protocolSection.designModule.parameters.designModule.phases,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.designModule.parameters.designModule.studyType,FP,FP,,INTERVENTIONAL,False,0.0,,,protocolSection.designModule.parameters.designModule.studyType,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.parameters.eligibilityModule.eligibilityCriteria,FP,FP,,"Inclusion Criteria:
- Age ≥ 9 years
- Moderate (Evaluator's Global Severity Score [EGSS] 3) or severe (EGSS 4) acne
- Facial inflammatory lesions: ≥ 30 to ≤ 100 (pustules, papules, and nodules)
- Facial noninflammatory lesions: ≥ 35 to ≤ 150 (closed and open comedones)
- Two or fewer nodules

Exclusion Criteria:
- Not explicitly stated in the provided content, but participants were required to meet all inclusion criteria to be eligible for enrollment",False,0.0,,,protocolSection.eligibilityModule.parameters.eligibilityModule.eligibilityCriteria,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.parameters.eligibilityModule.healthyVolunteers,FP,FP,,False,False,0.0,,,protocolSection.eligibilityModule.parameters.eligibilityModule.healthyVolunteers,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.parameters.eligibilityModule.maximumAge,FP,FP,,N/A,False,0.0,,,protocolSection.eligibilityModule.parameters.eligibilityModule.maximumAge,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.parameters.eligibilityModule.minimumAge,FP,FP,,9 Years,False,0.0,,,protocolSection.eligibilityModule.parameters.eligibilityModule.minimumAge,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.parameters.eligibilityModule.sex,FP,FP,,ALL,False,0.0,,,protocolSection.eligibilityModule.parameters.eligibilityModule.sex,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.eligibilityModule.parameters.eligibilityModule.stdAges,FP,FP,,"['CHILD', 'ADULT']",False,0.0,,,protocolSection.eligibilityModule.parameters.eligibilityModule.stdAges,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.parameters.outcomesModule.otherOutcomes,FP,FP,,"[{'measure': 'Treatment-emergent adverse events (TEAEs)', 'description': 'Evaluation of all adverse events reported during the study period', 'timeFrame': 'Throughout 12 weeks'}, {'measure': 'Cutaneous safety assessments', 'description': 'Investigator-assessed cutaneous safety (scaling, erythema, hypopigmentation, and hyperpigmentation) evaluated via a 4-point scale where 0 = none and 3 = severe', 'timeFrame': 'Baseline, weeks 2, 4, 8, and 12'}, {'measure': 'Cutaneous tolerability assessments', 'description': 'Participant-reported tolerability (itching, burning, and stinging) evaluated via a 4-point scale where 0 = none and 3 = severe', 'timeFrame': 'Baseline, weeks 2, 4, 8, and 12'}]",False,0.0,,,protocolSection.outcomesModule.parameters.outcomesModule.otherOutcomes,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.parameters.outcomesModule.primaryOutcomes,FP,FP,,"[{'measure': 'Treatment success', 'description': ""Percentage of participants achieving a ≥ 2-grade reduction from baseline in Evaluator's Global Severity Score (EGSS) and a score of 0 (clear) or 1 (almost clear)"", 'timeFrame': 'Week 12'}, {'measure': 'Absolute change from baseline in inflammatory lesion counts', 'description': 'Least-squares mean absolute change from baseline to week 12 in inflammatory lesion counts (pustules, papules, and nodules)', 'timeFrame': 'Baseline to week 12'}, {'measure': 'Absolute change from baseline in noninflammatory lesion counts', 'description': 'Least-squares mean absolute change from baseline to week 12 in noninflammatory lesion counts (closed and open comedones)', 'timeFrame': 'Baseline to week 12'}]",False,0.0,,,protocolSection.outcomesModule.parameters.outcomesModule.primaryOutcomes,True,False,True,False,False,False
Claude-4.5-Sonnet,protocolSection.outcomesModule.parameters.outcomesModule.secondaryOutcomes,FP,FP,,"[{'measure': 'Treatment success by study visit', 'description': ""Percentage of participants achieving a ≥ 2-grade reduction from baseline in Evaluator's Global Severity Score (EGSS) and a score of 0 (clear) or 1 (almost clear) at each study visit"", 'timeFrame': 'Baseline, weeks 2, 4, 8, and 12'}, {'measure': '≥ 2-grade reduction in EGSS by study visit', 'description': ""Percentage of participants achieving a ≥ 2-grade reduction from baseline in Evaluator's Global Severity Score (EGSS) at each study visit"", 'timeFrame': 'Baseline, weeks 2, 4, 8, and 12'}, {'measure': 'Percent change from baseline in inflammatory lesion counts by study visit', 'description': 'Percent change from baseline in inflammatory lesion counts at each study visit', 'timeFrame': 'Baseline, weeks 2, 4, 8, and 12'}, {'measure': 'Percent change from baseline in noninflammatory lesion counts by study visit', 'description': 'Percent change from baseline in noninflammatory lesion counts at each study visit', 'timeFrame': 'Baseline, weeks 2, 4, 8, and 12'}, {'measure': 'Acne-Specific Quality of Life (Acne-QoL) questionnaire', 'description': 'Assessment of health-related quality of life covering four domains (self-perception, role-emotional, role-social, and acne symptoms) where a higher score indicates improved quality of life', 'timeFrame': 'Baseline and week 12'}]",False,0.0,,,protocolSection.outcomesModule.parameters.outcomesModule.secondaryOutcomes,True,False,True,False,False,False
